

QIBA FDG-PET Biomarker Committee Call

03 February 2017 at 9 AM CT

Draft Call Summary

In attendance:

Rathan Subramaniam, MD, PhD, MPH (co-chair)

John Sunderland, PhD (co-chair)

Scott Wollenweber, PhD (co-chair)

Baderaldeen Altazi

Janice Campbell, PhD

Jerry Froelich, MD

John Hoffman, MD

Paul Kinahan, PhD

Martin Lodge, PhD

Nancy Obuchowski, PhD

Amy Perkins, PhD

Eric Perlman, MD

Anne Smith, PhD

Na Sun, PhD

Mitsuaki Tatsumi, MD

John Wolodzko, PhD

Richard Wahl, MD

Jeffrey Yap, PhD

Brian Zimmerman, PhD

RSNA

Joe Koudelik

Tori Peoples

Guest

Jeff Pohlhammer, PhD

Moderator: Dr. Sunderland

Profile Status

- The Profile feedback provided by Drs. Perkins and Pohlhammer (Philips) was discussed
- Modification of the DICOM format description (line 956) required clarification; the Profile was deemed a complicated process to follow regarding DICOM asks for system vendors, e.g. terminology across vendor platforms are not consistent even for the same DICOM label; additional wordsmithing to clarify or simplify was requested
- Additional technical specs that still need resolution included lean body mass and blood glucose level; whether additional studies were needed to support this text was not clear
- Profile format was reviewed
 - General, or descriptive text, was considered background information for users
 - Text confined to tables was normative, or of high priority
 - Gray tables contain future spec requirements (i.e. ideal conditions) that are not needed today for conformance
- To a newer Profile end-user, much of the temporary place holder language made the Profile seen in a draft state, not ready for implementation
- Differing opinions were expressed regarding the quantitative nature of FDG-PET
- Drs. Kinahan and Pohlhammer to follow up off line regarding vendor details in the Appendix
- Incorrect attribute name regarding “administered radiotracer” needed attention (Profile page 79, bullet #6)
- Use of “series time” and or “acquisition time” when discussing decay correction (page 40) was confusing since vendors used both terms; lines 927-930 were not consistent and need to be revisited
- Series Time is not a current DICOM choice for some vendors and needs to be changed
- Profile must also be seen as stable before being adopted in clinical trials and practice

NM CC Report-Out Slide for the Steering Cmte

- The FDG-PET status update slides were reviewed
- Progress has been made regarding multiple checklists and a technically confirmed Profile status
- Unanticipated issues such as point-spread-function and lean-body-mass were discussed
- Length of time and effort to complete the Profile was not anticipated
- The NM CC welcomes any process feedback from BC members; e.g. perfect vs good mentality
- Profile implementation remains a challenge in clinical trials and clinical care
- BC members need to network and move the Profile into practice
- A small ~40 patient test-retest trial across 5 sites would be statistically rigorous to test assumptions underlying the claim and inform whether the Profile is achievable

Manuscript Update (Dr. Kinahan)

- Manuscript is nearly done; RSNA Annual Meeting and the Moonshot Initiative efforts caused slight delays
- Manuscript to be circulated for feedback in 1-2 weeks

Nuclear Medicine WebEx Schedule:

Feb 10: Amyloid BC

Feb 24: NM Leadership / TBD

Mar 03: FDG-PET BC